Compare UVV & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UVV | CVAC |
|---|---|---|
| Founded | 1886 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | UVV | CVAC |
|---|---|---|
| Price | $53.17 | $4.32 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 160.0K | ★ 1.7M |
| Earning Date | 02-09-2026 | 11-24-2025 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | ★ 4.44 | 0.94 |
| Revenue | ★ $2,987,411,000.00 | $83,000,117.00 |
| Revenue This Year | $3.21 | N/A |
| Revenue Next Year | $1.02 | $23.71 |
| P/E Ratio | $11.98 | ★ $4.59 |
| Revenue Growth | ★ 3.01 | N/A |
| 52 Week Low | $49.40 | $2.48 |
| 52 Week High | $67.33 | $5.72 |
| Indicator | UVV | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 31.39 |
| Support Level | $52.93 | $4.00 |
| Resistance Level | $55.14 | $4.36 |
| Average True Range (ATR) | 0.81 | 0.16 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 36.09 | 22.51 |
Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.